Axillary lymph node dissection in breast cancer patients: obsolete or still necessary?
作者信息
Vanni Gianluca, Pellicciaro Marco, Buonomo Oreste Claudio
机构信息
Breast Unit Policlinico Tor Vergata, Department of Surgical Science, Tor Vergata University, Viale Oxford 81, 00133, Rome, RM, Italy.
PhD Program in Applied Medical-Surgical Sciences, Department of Surgical Science, Tor Vergata University, Rome, RM, Italy.
出版信息
Lancet Reg Health Eur. 2024 Oct 17;47:101107. doi: 10.1016/j.lanepe.2024.101107. eCollection 2024 Dec.
Abstract
摘要
相似文献
1
Axillary lymph node dissection in breast cancer patients: obsolete or still necessary?乳腺癌患者的腋窝淋巴结清扫术：过时了还是仍然必要？
Lancet Reg Health Eur. 2024 Oct 17;47:101107. doi: 10.1016/j.lanepe.2024.101107. eCollection 2024 Dec.
2
Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).腋窝淋巴结清扫与 T1N0 乳腺癌患者不清扫的随机临床试验（INT09/98）。
Cancer. 2014 Mar 15;120(6):885-93. doi: 10.1002/cncr.28499. Epub 2013 Dec 5.
3
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.腋窝淋巴结清扫术与非腋窝淋巴结清扫术对浸润性乳腺癌伴前哨淋巴结转移女性患者10年总生存率的影响：美国外科医师学会肿瘤学组Z0011（联盟）随机临床试验
JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.
4
Is axillary lymph node dissection necessary for positive preoperative aspiration cytology lymph node results?术前细针抽吸细胞学检查阳性的腋窝淋巴结是否需要进行腋窝淋巴结清扫？
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):504-510. doi: 10.1016/j.ejso.2019.10.043. Epub 2019 Nov 1.
5
6
Dissection of Level III Axillary Lymph Nodes in Breast Cancer.乳腺癌腋窝Ⅲ级淋巴结清扫术
Cancer Manag Res. 2021 Feb 26;13:2041-2046. doi: 10.2147/CMAR.S290345. eCollection 2021.
7
[Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].[早期浸润性乳腺癌前哨淋巴结活检阳性后腋窝的最佳治疗。OTOASOR试验的早期结果]
Orv Hetil. 2013 Dec 8;154(49):1934-42. doi: 10.1556/OH.2013.29765.
8
Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level.最大限度减少腋窝淋巴结阳性乳腺癌患者腋窝清扫的范围和发病率：基于乳腺淋巴管水平的腋窝淋巴结清扫术的实施。
BMC Cancer. 2021 Mar 19;21(1):293. doi: 10.1186/s12885-021-08024-y.
9
Axillary lymph node dissection in patients with breast cancer and sentinel lymph node micrometastasis or isolated tumor cells: is it necessary?乳腺癌伴前哨淋巴结微转移或孤立肿瘤细胞患者的腋窝淋巴结清扫：有必要吗？
Tumori. 2012 May-Jun;98(3):320-3. doi: 10.1177/030089161209800307.
10
Axillary lymph node dissection: does it have a role in primary breast cancer?腋窝淋巴结清扫术：它在原发性乳腺癌中起作用吗？
Am Surg. 1996 Feb;62(2):159-61.
引用本文的文献
1
Ultrasound-based radiomics combined with B3GALT4 level to predict sentinel lymph node metastasis in primary breast cancer.基于超声的影像组学联合B3GALT4水平预测原发性乳腺癌前哨淋巴结转移
Front Oncol. 2025 Jul 11;15:1570493. doi: 10.3389/fonc.2025.1570493. eCollection 2025.
2
Evaluating Tumor Size to Ki67 Proliferation Index Ratio for Optimizing Surgical Axillary Treatment Decisions in Breast Cancer Patients.评估肿瘤大小与Ki67增殖指数之比以优化乳腺癌患者腋窝手术治疗决策
Cancers (Basel). 2025 Feb 26;17(5):798. doi: 10.3390/cancers17050798.
本文引用的文献
1
Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trial.雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌的腋窝清扫率和化疗率：SENOMAC试验的二次分析
Lancet Reg Health Eur. 2024 Sep 26;47:101083. doi: 10.1016/j.lanepe.2024.101083. eCollection 2024 Dec.
2
Ribociclib plus Endocrine Therapy in Early Breast Cancer.瑞博西尼联合内分泌治疗早期乳腺癌
N Engl J Med. 2024 Jun 20;390(23):2220. doi: 10.1056/NEJMc2404917.
3
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.省略腋窝清扫术治疗前哨淋巴结转移乳腺癌。
N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487.
4
Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.前哨淋巴结活检与阴性超声腋窝淋巴结结果的小乳腺癌患者不进行腋窝手术的比较：SOUND 随机临床试验。
JAMA Oncol. 2023 Nov 1;9(11):1557-1564. doi: 10.1001/jamaoncol.2023.3759.
5
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.阿贝西利联合内分泌治疗激素受体阳性、HER2 阴性、淋巴结阳性、高危早期乳腺癌（monarchE）：一项随机、开放标签、III 期临床试验的预先计划的中期分析结果。
Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6.
6
Axillary Staging Is Not Justified in Postmenopausal Clinically Node-Negative Women Based on Nodal Disease Burden.基于淋巴结疾病负担，绝经后临床淋巴结阴性的女性进行腋窝分期没有依据。
Ann Surg Oncol. 2023 Jan;30(1):92-97. doi: 10.1245/s10434-022-12203-x. Epub 2022 Jul 25.
7
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.21 基因检测在淋巴结阳性乳腺癌中预测化疗获益。
N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1.
8
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.腋窝淋巴结清扫术与非腋窝淋巴结清扫术对浸润性乳腺癌伴前哨淋巴结转移女性患者10年总生存率的影响：美国外科医师学会肿瘤学组Z0011（联盟）随机临床试验
JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.
Zotero 插件